Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.37 |
| ▸ | SMO | Q99835 | 1/20 | 0.36 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 3/20 | 0.33 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL275522 | 0.91 | GLP1R (0.38) | GLP1RCHRM4PDE10ASMOSLC9A1 | |
| SCHEMBL21713065 | 0.87 | SMO (0.40) | GLP1RPDE10ASMOSLC9A1MALT1 | |
| SCHEMBL275533 | 0.85 | PDE10A (0.54) | PDE10ASMO | |
| SCHEMBL275614 | 0.84 | CNR2 (0.38) | GLP1RPDE10ASMO | |
| SCHEMBL276023 | 0.82 | PDE10A (0.37) | GLP1RCHRM4PDE10ASMOMALT1 | |
| SCHEMBL2373792 | 0.73 | NPC1 (0.42) | PDE10A | |
| SCHEMBL2410948 | 0.71 | ITGB3 (0.45) | — | |
| SCHEMBL27656896 | 0.71 | HSD11B1 (0.51) | — | |
| SCHEMBL16334101 | 0.70 | ALDH1A1 (0.46) | PDE10A | |
| SCHEMBL20302450 | 0.67 | CHRM4 (0.75) | CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765766-B2 | Pyrimidine derivatives which are antagonists of the vitronectin receptor | GALAPAGOS NV (BE) | 2014-07-01 | — | — | US | disclosed |
| EP-1747222-B1 | PYRIMIDINE DERIVATIVES ANTAGONISTS OF VITRONECTIN RECEPTOR | GALAPAGOS NV (BE) | 2014-04-16 | — | — | EP | disclosed |
| EP-2368891-B1 | Pyrimidines derivatives as antagonists of the vitronectine receptors | GALAPAGOS NV (BE) | 2012-09-19 | — | — | EP | disclosed |
| US-20120115883-A1 | PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONISTS OF THE VITRONECTIN RECEPTOR | GALAPAGOS SAS | 2012-05-10 | — | — | US | disclosed |
| US-8133896-B2 | Pyrimidine derivatives which are antagonist of the vitronectin receptor | GALAPAGOS NV (BE) | 2012-03-13 | — | — | US | disclosed |
| EP-2368891-A1 | Pyrimidines derivatives as antagonists of the vitronectine receptors | Galapagos SAS (FR) | 2011-09-28 | — | — | EP | disclosed |
| US-20110039867-A1 | PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONIST OF THE VITRONECTIN RECEPTOR | GALAPAGOS SAS | 2011-02-17 | — | — | US | disclosed |
| US-7846932-B2 | treatment of retinopathy comprising administering drugs such as tert-butyl 3-[5-ethyl-6-[4-(5,6,7,8-tetrahydro-(1,8)naphthyridin-2-yl)-piperidin-1-yl]-pyrimidin-4-ylamino]-2-(4-methoxy benzoyl)-propionate | GALAPAGOS SAS (FR) | 2010-12-07 | — | — | US | disclosed |
| US-7825119-B2 | Bone disorders such as osteoporosis, tumors and cardiovascular disorders; 4-(2-carboxy-2-Boc-aminoethylamino)-6-piperidinopyrimidines such as tert-butyl 2-benzyloxycarbonylamino-3-[2,5-dimethoxy-6-(4-[1,8]naphthyridin-2-yl-piperidin-1-yl)pyrimidin-4-ylamino]-propionate | GALAPAGOS SAS (FR) | 2010-11-02 | — | — | US | disclosed |
| US-20100041675-A1 | treatment of retinopathy comprising administering drugs such as tert-butyl 3-[5-ethyl-6-[4-(5,6,7,8-tetrahydro-(1,8)naphthyridin-2-yl)-piperidin-1-yl]-pyrimidin-4-ylamino]-2-(4-methoxy benzoyl)-propionate | GALAPAGOS SAS | 2010-02-18 | — | — | US | disclosed |
| US-20080058348-A1 | Bone disorders such as osteoporosis, tumors and cardiovascular disorders; 4-(2-carboxy-2-Boc-aminoethylamino)-6-piperidinopyrimidines such as tert-butyl 2-benzyloxycarbonylamino-3-[2,5-dimethoxy-6-(4-[1,8]naphthyridin-2-yl-piperidin-1-yl)pyrimidin-4-ylamino]-propionate | PROSKELIA SAS | 2008-03-06 | — | — | US | disclosed |
| EP-1747222-A1 | PYRIMIDINE DERIVATIVES ANTAGONISTS OF VITRONECTIN RECEPTOR | Proskelia SAS (FR) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005123734-A1 | PYRIMIDINE DERIVATIVES ANTAGONISTS OF VITRONECTIN RECEPTOR | PROSKELIA SAS (FR) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041675-A1 | treatment of retinopathy comprising administering drugs such as tert-butyl 3-[5-ethyl-6-[4-(5,6,7,8-tetrahydro-(1,8)naphthyridin-2-yl)-piperidin-1-yl]-pyrimidin-4-ylamino]-2-(4-methoxy benzoyl)-propionate | TBXA2R, GPR55, ADGRE5 | GLP1R 87/4885CHRM4 202/4885PDE10A 1311/4885 |
| US-20110039867-A1 | PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONIST OF THE VITRONECTIN RECEPTOR | P2RY1, P2RY2, P2RX5 | GLP1R 1022/4885CHRM4 196/4885PDE10A 2683/4885 |
| US-20120115883-A1 | PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONISTS OF THE VITRONECTIN RECEPTOR | P2RY1, P2RY2, P2RX5 | GLP1R 1102/4885CHRM4 203/4885PDE10A 2681/4885 |
| US-20080058348-A1 | Bone disorders such as osteoporosis, tumors and cardiovascular disorders; 4-(2-carboxy-2-Boc-aminoethylamino)-6-piperidinopyrimidines such as tert-butyl 2-benzyloxycarbonylamino-3-[2,5-dimethoxy-6-(4-[1,8]naphthyridin-2-yl-piperidin-1-yl)pyrimidin-4-ylamino]-propionate | CALCR, PTH1R, CALCRL | GLP1R 166/4885CHRM4 467/4885PDE10A 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.